EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases

September 16-21, 2021; Virtual
In patients with colorectal cancer and unresectable liver metastases, the addition of transarterial radioembolization with yttrium-90 to second-line chemotherapy demonstrated significant improvements in PFS and hepatic PFS with a higher rate of grade ≥3 toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 317 KB
Released: October 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on dosing of regorafenib and TAS-102 for colorectal cancer (CRC).

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue